© Reuters. ADVENT CLOSE TO BUY GENERIC VERSIONS OF SANOFI
(Reuters) – Advent International holds the rope to resume Zentiva, the european subsidiary of generics of Sanofi (PA:SASY), which are also of interest to pharmaceutical companies and several other investment funds, reported on Friday the Financial Times, citing three sources aware of the discussions.
If the funds uk venture capital investment is successful , it will not be considered BC Partners, says the newspaper, adding that the latter could also improve its offer.
Sanofi playing Advent against BC Partners, ” he says. The price will not be the only factor taken into consideration when making a choice, according to three sources.
The agreement must still be finalized and is not guaranteed. Sanofi could decide to keep its subsidiary or, to choose another buyer, she added.
An agreement, subject to the approval of the board of directors, may be announced in the coming days.
In February, sources reported to Reuters that the laboratory, brazilian EMS and the indian Torrent Pharma were also in the running.
(Catherine Mallebay-Vacqueur for the French service)